Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals, is scheduled to present on Tuesday, August 11, 2020 at 1:10 p.m. ET.

To access a live webcast and subsequent archived recording of the presentation, please visit the “Investors & Media” section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFYTM mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date set for October 30, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005087/en/

Investor Contact:
Hannah Deresiewicz
[email protected]
212-362-1200

Source: Kala Pharmaceuticals, Inc.

You May Also Be Interested In

• Wolters Kluwer and Dentsu Soken Deliver CCH® Tagetik as Daihatsu Motor's Budget Management System
• Mini PC Brand VZMORE Makes Global Debut at ShowStoppers @ IFA 2026, Bringing Advanced Thermal Innovation to Mini PCs
• The Next New Listing Could Crown This Cycle’s Biggest Winners and Smart Wallets Already Moved